Business Wire
29 Jul 2026, 21:30 UTC · 8w ago
Verdict
Headline takes no side. We score GCTK +0.40 across two claims — moderately bullish.
+0.40moderately bullish
More positive than 64% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Lōkahi Therapeutics is evaluating a shift in LT-100 administration from up to 15 intradermal injections per visit to a single subcutaneous injection.
More positive than 93% of claims this week
The company held a Type C meeting with the U.S. FDA in May 2026 to discuss this development strategy.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 63% of claims this week
Which stocks this story touches
More positive than 64% of ticker scores this week
The company's subsidiary is making progress in simplifying the administration strategy for its LT-100 development.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
15h ago
−52.5%
Price is moving against the score
$2.03 vs $4.27 close before publication (Jul 29) · not market-adjusted
GCTK chart →
